ClinicalTrials.gg
RecruitingNCT07334379IDENTIFYUpdated Oct 9, 2026

Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study

A Phase 2 interventional study of Tocilizumab (Actemra®) and Dexamethasone in Acute Hypoxemic Respiratory Failure, sponsored by Lorenzo delSorbo. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Lorenzo delSorbo · Phase 2, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 9, 2026Primary completion movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies in Respiratory Insufficiency with a site in Canada — 24 open to participants now, 29 under way, 1 of them phase 3. Respiratory Insufficiency · Canada.

Planned enrollment
24th of 66
60 · median 31
Started
2025
with 5 others
Phase 2
4 of 94
3 open now
Primary completion
2027-02
later than 19 of 28 live
Registered
92nd of 94
by date
Lead sponsor
2 of 94
Lorenzo delSorbo

Among the 94 studies in Respiratory Insufficiency with a site in Canada, this one is the 24th largest by planned enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 19 of the 28 other live ones, and was the 92nd registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

24 of the 94 studies in Respiratory Insufficiency with a site in Canada are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Respiratory Insufficiency with a site in Canada, or all of them as a file.
02

Study summary

Acute hypoxemic respiratory failure (AHRF) happens when the lungs are unable to absorb enough oxygen. The bloodstream is deprived of oxygen which can eventually lead to more severe conditions like multi-organ failure (MOF) and death. AHRF accounts for over 30% of patients to critical care units, thus novel treatments are sorely needed. Research has shown that blood levels of the inflammatory biomarker Interleukin-6 (IL-6) may be a reliable marker for predicting which patients with AHRF will progress into requiring intensive care unit (ICU) admission, MOF, and eventually death. IL-6 levels were shown to reliably peak several days before MOF, ICU admission, and death. Thus, the investigators believe that by identifying patients before the peak of their IL-6 levels, they will be able to administer early treatment to prevent the patient's condition from worsening. The aim of this study is to test the feasibility of a treatment strategy for AHRF based on IL-6 measurement in patients who are admitted to hospital care with AHRF.

This study has two phases: 1) observational and 2) interventional.

In the observational phase 1, patients who meet the inclusion and a general exclusion criteria are eligible for participation. In the observational phase, patients will have their plasma IL-6 levels measured over 2 days. Patients' clinical condition will be observed till discharge or up to 28 days of admission, and data will be collected from their medical charts.

Patients participating in the observational phase 1 will be considered eligible to join the interventional phase 2 if: they are found to have elevated IL-6 levels, and they meet additional randomization exclusion criteria. In the interventional phase, patients will be randomized into 1 of 3 treatment groups: standard of care only, standard of care plus a single IV infusion of Tocilizumab, or standard of care plus treatment with oral Dexamethasone for 10 days. Patients' clinical condition will be observed till discharge or up to 28 days of admission, and data will be collected from their medical charts. A follow-up phone interview will be conducted 6 months of the end of the observation period.

Patients participating in the observational phase 1 who are not eligible to participate in the interventional phase 2 will continue in the observational phase 1 only. These patients will not be randomized to a group, receive any study medications, or be contacted for the 6-month follow-up.

03

Conditions studied

  • Acute Hypoxemic Respiratory Failure
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Presence of new onset of respiratory symptoms in the previous 14 days upon presentation at the emergency department. Respiratory symptoms are characterized by at least one of the following: cough, dyspnea, or requirement of oxygen supplementation
  3. Requirement of inpatient hospital management

Exclusion criteria

Exclusion Criteria

General Exclusion:

  1. Inability to provide
  2. Immediate need for admission to ICU
  3. Immediate need for intubation
  4. Imminent death
  5. Clinical team refusal

Randomization Exclusion

  1. Patients with known to dexamethasone or tocilizumab, or any of their components
  2. Allergic reaction to tocilizumab or other monoclonal antibodies
  3. Patients who are using azathioprine or cyclophosphamide
  4. Active tuberculosis infection
  5. or AST >10x
  6. \<1000/mcl
  7. count \<50,000/mm3
  8. Patients already receiving systemic , monoclonal antibodies or other medications at the time of presentation
  9. Inability to comply with the regulations to avoid conception within 28 days after enrollment
  10. Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
  11. Participation in other drug clinical trials (this criterion will be discussed with the PI)
  12. Reaching >72h since hospital admission
  13. Admission to ICU prior to randomization
  14. Pregnancy (positive pregnancy test) or breastfeeding (which is a contraindication to tocilizumab)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • No intervention
    Control

    Routine care only

  • Experimental
    Tocilizumab

    Routine care + single intravenous infusion of tocilizumab at a dose of 4mg/kg of body weight (up to a max 400mg).

    Drug: Tocilizumab (Actemra®)

  • Experimental
    Dexamethasone

    Routine care + a 10mg of oral dexamethasone per day for up to 10 days (or until hospital discharge).

    Drug: Dexamethasone

Interventions

  • DrugTocilizumabStudies of TocilizumabTocilizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects randomized to the tocilizumab arm will receive a single intravenous (IV) infusion of tocilizumab, given over 1 hour. The tocilizumab will be given at a dosage of 4mg per kg of body weight, up to a maximum dose of 400 mg.

  • Subjects randomized to the dexamethasone arm will receive 6 mg of dexamethasone per day, for up to 10 days, or until discharged from the hospital. Dexamethasone will be given in tablet form orally (by mouth) or through an equivalent method.

06

What researchers measure

Primary outcomes

  1. To determine the potential recruitment rate

    Time frame: From enrollment to completion of the study (in including the 6-month follow-up).

  2. To assess the proportion of eligible patients who do not have daily IL-6 measurement

    Time frame: Baseline (Day 0) to Day 2

  3. To assess the proportion of eligible patients who are not randomized

    Time frame: Baseline (Day 0) to Day 2

  4. To determine the rate of adherence to the assigned treatment strategy and any cross-overs

    Time frame: Baseline to end of 28-day observation period (or hospital discharge)

  5. To estimate the time from hospital admission to randomization and initiation of the allocated treatment

    Time frame: Baseline to Day 3

Secondary outcomes

  1. All cause 28-day mortality

    Time frame: From enrollment to completion of the 28-day observation period (or hospital discharge).

  2. Sequential Organ Failure Assessment (SOFA) score increase of ≥2 or death

    The SOFA (Sequential Organ Failure Assessment) scale is used to assess a patient's organ function. The SOFA score is based on 6 different systems: respiratory, cardiovascular, hepatic, coagulation, renal, and neurological. Each system is given a score from 0 (best) to 4 (worst). Total SOFA score is calculated by adding the scores for each system, with a lower total SOFA scores generally denote better overall organ function.

    Time frame: From enrollment to end of 28-day observation period (or hospital discharge).

  3. Development of ARDS or death

    Time frame: From enrollment to end of 28-day observation period (or hospital discharge).

  4. ICU admission or death

    Time frame: From enrollment to end of 6-month follow-up period.

  5. Hospital length of stay

    Time frame: From enrollment to end of 28-day observation period (or hospital discharge).

  6. ICU length of stay

    Time frame: From enrollment to end of 28-day observation period (or hospital discharge).

  7. Need for invasive mechanical ventilation or death

    Time frame: From enrollment to end of 28-day observation period (or hospital discharge).

  8. Duration of invasive mechanical ventilation

    Time frame: From enrollment to end of 28-day observation period (or hospital discharge).

  9. Health related quality of life at 6 months assessed using the 36-Item Short Form Survey (SF-36)

    The SF-36 is a 36-item survey that scores patients on eight health scales: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. The SF-36 is structured so higher scores on each scale generally denote a more favorable health outcome. It also includes a single item that provides an indication of perceived change in health.

    Time frame: From enrollment to 6 months after the end of 28-day observation period (or hospital discharge)

  10. Survival at 6 months

    Time frame: From enrollment to end of 6-month follow-up period.

  11. Complications of steroids or tocilizumab including

    Complications including: Hypersensitivity or allergic reaction to tocilizumab, Nosocomial infections, Neuromuscular weakness, Gastrointestinal perforations.=, Hypernatremia (serum sodium \>150 mmol/L), Hyperglycemia (requiring new insulin or increased insulin dose), Hepatic dysfunction, Demyelinating disorders, Myocardial infarction or acute coronary syndrome, Malignancies, Stroke, New delirium, Neuromuscular weakness, Clinically significant gastrointestinal bleeding (requiring transfusion or endoscopy), Fetal and infant harm, and Death

    Time frame: From enrollment to end of 28-day observation period (or hospital discharge).

Other outcomes

  1. To assess reasons why eligible patients are not randomized

    In addition to primary outcome #3: To assess the proportion of eligible patients who are not randomized, the reasons why eligible patients are not randomized will also be recorded.

    Time frame: Baseline (Day 0) to Day 2.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 16 months after the start.

Of 30 phase 2 interventional studies under Respiratory Insufficiency, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 16 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Feb 2027, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Jan 12, 2026
StartActual
Oct 20, 2025
Primary completionEst.
Feb 20, 2027was Oct 2026
CompletionEst.
Feb 26, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 20, 2026→Feb 20, 2027
Oct 9, 2026
Eligibility
1 exclusion criterion edited, 4 added, 8 removed
What changed in the criteria
Exclusion criteria
  • AddedGeneral Exclusion:
  • AddedImmediate need for admission to ICU
  • AddedRandomization Exclusion
  • RemovedPatients who have active hepatic disease or hepatic impairment
  • EditedALT or AST >3x10x upper limit of normal
  • RemovedHemoglobin (Hb) below 8.5 g/dL,
  • RemovedWhite blood cell count (WBC) below 3000/mm3
  • RemovedAbsolute Neutrophil Count (ANC) below 2.0 x 109/L
  • Removedabsolute lymphocyte count below 500/mm3
  • Removedtotal bilirubin above ULN
  • RemovedTriglycerides (TG) above 10 mmol/L (above 900 mg/dL)
  • RemovedSerum creatinine above 1.4 mg/dL in female patients and above 1.6 mg/dL in male patients
  • AddedAny serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Oct 20, 2026→Feb 20, 2027
    Eligibility 1 exclusion criterion edited, 4 added, 8 removed
    What changed in the criteria
    Exclusion criteria
    • AddedGeneral Exclusion:
    • AddedImmediate need for admission to ICU
    • AddedRandomization Exclusion
    • RemovedPatients who have active hepatic disease or hepatic impairment
    • EditedALT or AST >3x10x upper limit of normal
    • RemovedHemoglobin (Hb) below 8.5 g/dL,
    • RemovedWhite blood cell count (WBC) below 3000/mm3
    • RemovedAbsolute Neutrophil Count (ANC) below 2.0 x 109/L
    • Removedabsolute lymphocyte count below 500/mm3
    • Removedtotal bilirubin above ULN
    • RemovedTriglycerides (TG) above 10 mmol/L (above 900 mg/dL)
    • RemovedSerum creatinine above 1.4 mg/dL in female patients and above 1.6 mg/dL in male patients
    • AddedAny serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
    + 2 other changes: description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07334379
Lead sponsor
Lorenzo delSorbo
Collaborators
Roche Diagnostic Ltd.
Responsible party
Lorenzo delSorbo (MD, Critical Care Medicine Department, Toronto General Hospital, University Health Network, Toronto) — Sponsor-investigator
First posted
Jan 12, 2026
Start date
Oct 20, 2025
Primary completion
Feb 20, 2027 (estimated)
Completion
Feb 26, 2027 (estimated)
Last update
Oct 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tocilizumab · Dexamethasone

Start the discussion